Patent · US Active

Oligonucleotide analogues targeting human LMNA

US10076536B2 · kind B2 · utility

2Cited by
27References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 15, 2017
Grant dateSep 18, 2018
Priority date—
Expiry dateMay 15, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.